Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Non-Current Assets (2020 - 2025)

Universe Pharmaceuticals' Non-Current Assets history spans 6 years, with the latest figure at $15.7 billion for Q3 2025.

  • On a quarterly basis, Non-Current Assets fell 3.77% to $15.7 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $15.7 billion, a 3.77% decrease, with the full-year FY2025 number at $15.7 billion, down 3.77% from a year prior.
  • Non-Current Assets hit $15.7 billion in Q3 2025 for Universe Pharmaceuticals, down from $16.3 billion in the prior quarter.
  • Over the last five years, Non-Current Assets for UPC hit a ceiling of $16.3 billion in Q3 2024 and a floor of $15.9 million in Q1 2024.
  • Historically, Non-Current Assets has averaged $4.0 billion across 5 years, with a median of $18.8 million in 2021.
  • Biggest five-year swings in Non-Current Assets: plummeted 100.0% in 2021 and later skyrocketed 99054.25% in 2024.
  • Tracing UPC's Non-Current Assets over 5 years: stood at $19.7 million in 2021, then dropped by 8.29% to $18.0 million in 2022, then decreased by 8.76% to $16.5 million in 2023, then skyrocketed by 99054.25% to $16.3 billion in 2024, then decreased by 3.77% to $15.7 billion in 2025.
  • Business Quant data shows Non-Current Assets for UPC at $15.7 billion in Q3 2025, $16.3 billion in Q3 2024, and $15.9 million in Q1 2024.